Use Auxilium Pharmaceuticals Inc. media headlines with your portfolios to protect against small markets fluctuations as well as to determine Stock diversification method that is right for you.
Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the US FDA seeking approval to market Testosterone Gel, 1%.
Auxilium Pharmaceuticals Inc. and FCB filed a lawsuit Wednesday against Watson Pharmaceuticals and its subsidiary Watson Laboratories for allegedly infringing on 10 FCB patents for the testosterone gel Testim.
Auxilium Pharmaceuticals and FCB I File Lawsuit Against Watson for ...
Benzinga - 20 hours ago
By Eddie Staley Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) and FCB I LLC announced today that they filed a lawsuit against Watson Laboratories, Inc. (NV); Watson Pharmaceuticals, Inc. (NYSE: WPI); and Watson Pharma, Inc. for infringement of FCB's ...
Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) and FCB I LLC have filed a lawsuit against Watson Laboratories, Inc. (NV); Watson Pharmaceuticals, Inc.; and Watson Pharma, Inc. (NYSE: WPI) for infringement of FCB's ten patents listed in the US Food and ...
Auxilium Pharmaceuticals, Inc. and FCB I LLC File Lawsuit Against Watson for ...
MarketWatch (press release) - 20 hours ago
MALVERN, Pa., and WILMINGTON, Del., May 24, 2012 /PRNewswire via COMTEX/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) ("Auxilium") and FCB I LLC ("FCB") announced today that they filed a lawsuit against Watson Laboratories, Inc. (NV); ...
Specialty pharmaceutical company Auxilium Pharmaceuticals (NASDAQ: AUXL) has inked a deal with with GlaxoSmithKline (NYSE: GSK) to co-promote its testeosterone replacement therapy gel Testim in a bid to grab a bigger slice of the primary care physician ...
By DOW JONES NEWSWIRES Auxilium Pharmaceuticals Inc. (AUXL) raised its full-year outlook as it entered an agreement with the US unit of GlaxoSmithKline PLC (GSK) to co-promote a testosterone replacement therapy.
Auxilium Pharmaceuticals, Inc. and GlaxoSmithKline LLC Enter Into a Co ...
MarketWatch (press release) - 10 hours ago
MALVERN, Pa. and PHILADELPHIA, May 21, 2012 /PRNewswire via COMTEX/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) and GlaxoSmithKline LLC, the US subsidiary of GlaxoSmithKline plc (LSS:UK:GSK) , announced today that they have entered into an ...
Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss ... - Sacramento Bee
Private Equity Hub (press release) - May 18, 2012
Austin-based Respira Therapeutics Inc. has added Armando Anido, the former president and chief executive of Auxilium Pharmaceuticals Inc., to its board of directors.
AUXILIUM PHARMACEUTICALS, INC. : Armando Anido Joins Respira Therapeutics, Inc ... - 4-traders
A Forward Look, The Year Ahead - Featured Research on Auxilium Pharmaceuticals ...
Business Review USA (press release) - May 18, 2012
HONG KONG--(Marketwire - May 17, 2012) - Today, www.BollingerReport.com introduced featured coverage of Auxilium Pharmaceuticals, Inc. ( NASDAQ : AUXL ) and Prestige Brands Holdings, Inc. ( NYSE : PBH ). Full research reports are available to readers ...
Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of ...
MarketWatch (press release) - May 17, 2012
MALVERN, Pa. and MAHWAH, NJ, May 17, 2012 /PRNewswire via COMTEX/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) ("Auxilium") and FCB I LLC ("FCB") today announced that the United States Patent and Trademark Office ("USPTO") has issued US Patent No.
AUXILIUM PHARMACEUTICALS, INC. : and FCB I LLC Announce the Issuance of ... - 4-traders
Sacramento Bee - May 17, 2012
By Respira Therapeutics, Inc. AUSTIN, Texas, May 16, 2012 -- /PRNewswire/ -- Respira Therapeutics, Inc. (http://www.respiratherapeutics.
Junction Report - May 15, 2012
Auxilium Pharma (NASDAQ: AUXL)'s stock had its ?neutral? rating restated by Zacks in a research report issued to clients and investors on Tuesday.
Zacks.com - May 14, 2012
Auxilium Pharmaceuticals, Inc. (AUXL - Analyst Report) reported a first quarter loss of 4 cents per share, well below the year-ago loss of 25 cents and the Zacks Consensus Estimate of a loss of 12 cents.
Canaccord Genuity Reaffirms Buy Rating on Auxilium Pharma (AUXL) - Daily Political
Auxilium Pharmaceuticals Inc. is rated fifth in revenue category among related companies. Market size based on revenue of Drug Related Products industry is presently estimated at about 8.36 Billion. Auxilium holds roughly 279.55 Million in revenue claiming about 3% of equities under Drug Related Products industry.
Auxilium Research Report
Auxilium Total Debt
Based on latest financial disclosure Auxilium Pharmaceuticals Inc. has Total Debt of 0.0. This is 100.0% lower than that of Healthcare sector, and 100.0% lower than that of Drug Related Products industry, The Total Debt for all stocks is 100.0% higher than the company.
In most industries, total debt may also include current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meaningful to compare total debt amounts between companies that operate within the same sector.
USA 
Equity Search
Advanced Search
Market Screener
Adviser Directory
Suggest Portfolio
Backtest Watchlist
Analyze Correlations
View Transactions
Check Volatility
Import Equities
Summary
Fundamentals
Technicals
Performance
Valuation
Volatility
History
News
Management
Discussion
